9987 Carver Road
About Aerpio TherapeuticsAerpio Therapeutics is a new, clinical-stage biotechnology company focused on the development of novel small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing. Aerpio was created in a spin-out transaction from Akebia Therapeutics to enable more rapid development of its exciting compounds.
Aerpio's two lead programs include a Tie-2 activator for diabetic macular edema (DME) and vascular leak, and a Hypoxia-inducible Factor 1-a (HIF1-a) stabilizer for wound healing and the treatment of inflammatory bowel disease. The lead compound for the Tie-2 program, AKB-9778, is currently completing its initial Phase 1 clinical trial, and the HIF1-a stabilization program is progressing toward the clinic with support, in part, from the United States Department of Defense and National Institutes of Health.
The Aerpio team is composed of highly experienced individuals from all facets of pharmaceutical development. During the last 4 years, this team has successfully sharpened their skills at Akebia Therapeutics in the fast paced world of venture backed biopharmaceuticals.
51 articles with Aerpio Therapeutics
Aerpio Pharmaceuticals, Inc. (“Aerpio”) (Nasdaq: ARPO) announced that Aadi Bioscience (“Aadi”), a privately-held biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today issued a press release disclosing its abstract to be presented at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting.
Aerpio Pharmaceuticals, Inc., a biopharmaceutical company focused on developing compounds that activate Tie2, and Aadi Bioscience, Inc., a privately-held biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, announced their entry into a definitive merger agreement.
3/15/2021It was another busy week for clinical trial announcements. Here’s a look including trials for COVID-19, migraine, Parkinson's disease, Alzheimer's, HIV and more.
6/29/2020It was a busy week for clinical trial updates. Here’s a look.
Aerpio Pharmaceuticals, Inc. (“Aerpio”) (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases, ARDS associated with COVID-19, and diabetic complications, today announced that it has commenced patient enrollment in its double-blind, placebo-controlled Phase 2 trial in patients with elevated intraocular pressure (IOP) associated with open angle glaucoma (OAG) or ocular hypertension (OH
Aerpio Pharmaceuticals, Inc. (“Aerpio”) (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, today announced that it is hosting a key opinion leader (KOL) call on a novel mechanism for the treatment of glaucoma on Friday, June 12, 2020 at 11:30am Eastern Time. The call will feature presentations by Dr. Paul Kaufman M.D. (University of Wisconsin) and
Aerpio Initiates Phase 1b Clinical Trial of Topical Ocular Formulation of AKB-9778 for Primary Open Angle Glaucoma
Aerpio Pharmaceuticals, Inc. announced dosing of the first subject in a Phase 1b trial of a topical ocular formulation of AKB-9778 in development for treatment of primary open angle glaucoma.
On Track to Initiate Phase 1b Clinical Trial of Topical Drop Formulation of AKB-9778 for Primary Open-Angle Glaucoma (POAG) in the Second Quarter of 2019
Aerpio Pharmaceuticals Presents Data Showing Potential of AKB-9778, a VE-PTP Inhibitor/Tie2 Activator, to Lower Intra-ocular Pressure in Human Subjects
Data presented during “The Role of the Tie2 Pathway in Ocular Disease” symposium at the Association for Research in Vision and Ophthalmology (ARVO) 2019 Annual Meeting
Aerpio Pharmaceuticals to Present Data Demonstrating Role of VE-PTP in Conventional Outflow Homeostasis and the Potential of AKB-9778, a VE-PTP Inhibitor/Tie2 Activator, as a Treatment for Open-Angle Glaucoma
Data to be presented at the Association for Research in Vision and Ophthalmology (ARVO) 2019 Annual Meeting
Aerpio Pharmaceuticals, Inc. announced that Chief Executive Officer, Stephen Hoffman, M.D., Ph.D., will present at the 18th Annual Needham Healthcare Conference on Wednesday, April 10, 2019 at 11:20 a.m. Eastern Time in New York, NY.
Aerpio said the Phase IIb asset did show some positive data in a number of pre-specified secondary endpoints, including changes in Urine Albumin-Creatinine Ratio, a measure of kidney function, and in intraocular pressure.
Top-Line Results from the TIME-2b Clinical Trial Evaluating the Effect of AKB-9778 in Patients with Non-Proliferative Diabetic Retinopathy (NPDR) Expected in March 2019
Aerpio Pharmaceuticals to Announce Fourth Quarter and Full Year 2018 Financial Results and Host Conference Call on Tuesday, March 5, 2019
Aerpio Pharmaceuticals, Inc. announced that its fourth quarter and full year 2018 financial results will be released before the market opens on Tuesday, March 5, 2019.
Aerpio Pharmaceuticals to Announce Third Quarter 2018 Financial Results and Host Conference Call on Wednesday, November 7, 2018
Aerpio Pharmaceuticals, Inc. today announced that its third quarter 2018 financial results will be released before the market opens on Wednesday, November 7, 2018.
Since it first launched with $100 million in the bank earlier this year, Gossamer Bio has been on something of a roll.
Aerpio Pharmaceuticals Announces Uplisting to Nasdaq Capital Market and Pricing of $45.0 Million Public Offering of Common Stock
Aerpio will begin trading on the Nasdaq Capital Market under the symbol “ARPO” at the opening of trading on June 26, 2018
This morning two companies announced deals that will yield potential benefits to multiple patient populations.
Aerpio Announces Initiation of Dosing in a Phase 1a, Multiple-Ascending Dose Study of AKB-4924, a Hypoxia-Inducible Factor-1 Alpha Stabilizer in Development for Inflammatory Bowel Disease
AKB-4924 is a once-daily, oral, gut-restricted HIF-1 alpha stabilizer that has been shown to improve disease indices in multiple models of inflammatory bowel disease.
TIME-2b Clinical Trial of AKB-9778 in Patients with Diabetic Retinopathy Remains on Track